GlassScriptPhysician profile
Vivek Jain
NPI 1871679373
$1,739.73
in general payments reported to CMS, 2019-2025
21 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.30 · 2021: $101 · 2022: $111 · 2023: $232 · 2024: $547 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.87 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.53 | 2021-2025 | |
| Pfizer INC. | $377.21 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $167.14 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $132.45 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $124.59 | 2024 | Ultomiris |
| Lilly USA, LLC | $97.83 | 2023-2025 | Kisunla, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $58.46 | 2022 | |
| Biogen, INC. | $57.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.06 | 2024 | Xarelto |
| Ucb, INC. | $40.62 | 2025 | Rystiggo |
| Neurocrine Biosciences, INC. | $34.83 | 2025 | |
| Janssen Biotech, INC. | $30.68 | 2023 | Stelara |
| Acadia Pharmaceuticals INC | $29.71 | 2025 | Daybue |
| Biohaven Pharmaceuticals, INC. | $28.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $26.96 | 2024 | Rytary |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $20.93 | 2023 | Arcalyst |
| Averitas Pharma INC. | $20.85 | 2023 | Qutenza |
| Livanova USA, INC. | $19.30 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.25 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $14.57 | 2024 | Spritam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.